Overview

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.